Intuitive Surgical is a pioneering medical device company specializing in robotic-assisted surgical systems, most notably the da Vinci Surgical System. This innovative platform enhances the precision and control of minimally invasive surgical procedures, enabling surgeons to perform operations with greater accuracy and reduced recovery times for patients. The company is dedicated to advancing the field of robotics in surgery, providing training and support for healthcare professionals, and continually innovating its technology to improve patient outcomes across various medical specialties. Read More
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with
This lesson-filled episode makes the case for capital "H" History as an investor's secret weapon -- and for why perspective, patience, and precise thinking continue year after year to help investors crush stock market averages.
SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing.
Some are dealing with declining demand, high costs, or regulatory pressures that could limit future upside.
As the trading floor lights flickered to life in early 2026, a new psychological benchmark took hold of the financial world: 8,000. Just two years after the S&P 500 first crossed the 5,000 threshold, a growing chorus of Wall Street’s most influential strategists is projecting that
As the 44th Annual J.P. Morgan Healthcare Conference kicked off this week in San Francisco, all eyes turned to UnitedHealth Group (NYSE:UNH), the diversified healthcare giant that serves as the primary barometer for the multi-trillion-dollar U.S. medical sector. On January 12, 2026, the company issued a critical
A cash-heavy balance sheet is often a sign of strength, but not always.
Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
The first trading week of 2026 has delivered a complex narrative for the technology sector, defined by a stark contrast between groundbreaking innovation and a massive institutional shift in capital. As the world gathered for the Consumer Electronics Show (CES) in Las Vegas, Nvidia Corp. (NASDAQ: NVDA) once again seized
As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun to fragment, giving way to a more discerning "Internal Repair" phase. Investors are increasingly rotating capital out of
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wall Street has issued downbeat forecasts for the stocks in this article.
These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
